ECSP088813A - Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 - Google Patents
Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2Info
- Publication number
- ECSP088813A ECSP088813A EC2008008813A ECSP088813A ECSP088813A EC SP088813 A ECSP088813 A EC SP088813A EC 2008008813 A EC2008008813 A EC 2008008813A EC SP088813 A ECSP088813 A EC SP088813A EC SP088813 A ECSP088813 A EC SP088813A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutically acceptable
- solvate
- hydrate
- inflammation
- allergic
- Prior art date
Links
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 title abstract 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 title abstract 2
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000004624 Dermatitis Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000007803 itching Effects 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula (I), en la que R1 y R2 son como se han definido en este documento, o una sal farmacéuticamente aceptable, hidrato o solvato del mismo, un profármaco farmacéuticamente aceptable del mismo, o una sal farmacéuticamente aceptable, hidrato o solvato del profármaco, una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz de uno o más compuestos de la invención mezclada con un vehículo farmacéuticamente aceptable, un método para tratar a un paciente que padece un trastorno mediado por PGD2 incluyendo, pero sin limitación, enfermedad alérgica (tal como rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, asma bronquial y alergia alimentaria), mastocitosis sistémica, trastornos acompañados por la activación sistémica de mastocitos, choque anafiláctico, broncoconstricción, bronquitis, urticaria, eccema, enfermedades acompañadas por picor (tales como dermatitis atópica y urticaria), enfermedades (tales como cataratas, desprendimiento de retina, inflamación, infección y trastornos del sueño) que se generan secundariamente como resultado del comportamiento que acompaña al picor (tal como rascarse y golpearse), inflamación, enfermedad pulmonar obstructiva crónica, lesión por isquemia-reperfusión, accidente cerebrovascular, artritis reumatoide crónica, pleuritis, colitis ulcerosa y similares, por medio de la administración a dicho paciente de una cantidad farmacéuticamente eficaz de un compuesto de la invención.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74467606P | 2006-04-12 | 2006-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088813A true ECSP088813A (es) | 2008-11-27 |
Family
ID=38294040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008813A ECSP088813A (es) | 2006-04-12 | 2008-10-09 | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090036469A1 (es) |
| EP (1) | EP2010503A1 (es) |
| JP (1) | JP2009533473A (es) |
| KR (1) | KR20080108287A (es) |
| CN (1) | CN101421252B (es) |
| AR (1) | AR060403A1 (es) |
| AU (1) | AU2007238052B2 (es) |
| BR (1) | BRPI0710710A2 (es) |
| CA (1) | CA2649083C (es) |
| CR (1) | CR10249A (es) |
| DO (1) | DOP2007000068A (es) |
| EC (1) | ECSP088813A (es) |
| HN (1) | HN2008001530A (es) |
| MA (1) | MA30409B1 (es) |
| MX (1) | MX2008011369A (es) |
| NO (1) | NO20084291L (es) |
| NZ (1) | NZ571793A (es) |
| PE (1) | PE20080186A1 (es) |
| RU (1) | RU2431631C2 (es) |
| TN (1) | TNSN08339A1 (es) |
| TW (1) | TW200815395A (es) |
| UA (1) | UA95950C2 (es) |
| UY (1) | UY30283A1 (es) |
| WO (1) | WO2007121280A1 (es) |
| ZA (1) | ZA200807380B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5039594B2 (ja) * | 2008-02-08 | 2012-10-03 | 株式会社日立ハイテクノロジーズ | レビュー装置，検査領域設定支援システム、および、欠陥の画像得方法 |
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| CA2793223A1 (en) * | 2010-03-16 | 2011-09-22 | Aventis Pharmaceuticals Inc. | Substituted pyrimidines as prostaglandin d2 receptor antagonists |
| MX2012010038A (es) * | 2010-03-16 | 2012-10-01 | Aventis Pharma Inc | Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2. |
| CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| CA2930008A1 (en) * | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
| MY195016A (en) | 2014-08-04 | 2023-01-03 | Nuevolution As | Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| AU2020347662B2 (en) * | 2019-09-13 | 2026-07-09 | Meiji Co., Ltd. | Solid food and solid milk |
| WO2021113710A1 (en) | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| BR112022012205A2 (pt) | 2019-12-20 | 2022-09-13 | Nuevolution As | Compostos ativos para receptores nucleares |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3644799A1 (de) * | 1986-06-04 | 1987-12-10 | Hoechst Ag | Neue pyrimidin-derivate, deren herstellung und verwendung |
| US5047554A (en) * | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
| SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
-
2007
- 2007-04-10 DO DO2007000068A patent/DOP2007000068A/es unknown
- 2007-04-10 AR ARP070101501A patent/AR060403A1/es not_active Application Discontinuation
- 2007-04-12 UA UAA200813109A patent/UA95950C2/ru unknown
- 2007-04-12 MX MX2008011369A patent/MX2008011369A/es active IP Right Grant
- 2007-04-12 NZ NZ571793A patent/NZ571793A/en not_active IP Right Cessation
- 2007-04-12 EP EP07760526A patent/EP2010503A1/en not_active Withdrawn
- 2007-04-12 JP JP2009505615A patent/JP2009533473A/ja not_active Abandoned
- 2007-04-12 PE PE2007000450A patent/PE20080186A1/es not_active Application Discontinuation
- 2007-04-12 CN CN2007800127354A patent/CN101421252B/zh not_active Expired - Fee Related
- 2007-04-12 AU AU2007238052A patent/AU2007238052B2/en not_active Expired - Fee Related
- 2007-04-12 WO PCT/US2007/066481 patent/WO2007121280A1/en not_active Ceased
- 2007-04-12 UY UY30283A patent/UY30283A1/es not_active Application Discontinuation
- 2007-04-12 TW TW096112790A patent/TW200815395A/zh unknown
- 2007-04-12 CA CA2649083A patent/CA2649083C/en not_active Expired - Fee Related
- 2007-04-12 RU RU2008144578/04A patent/RU2431631C2/ru not_active IP Right Cessation
- 2007-04-12 KR KR1020087024764A patent/KR20080108287A/ko not_active Withdrawn
- 2007-04-12 BR BRPI0710710-2A patent/BRPI0710710A2/pt not_active IP Right Cessation
-
2008
- 2008-08-26 CR CR10249A patent/CR10249A/es not_active Application Discontinuation
- 2008-08-27 TN TNP2008000339A patent/TNSN08339A1/en unknown
- 2008-08-27 ZA ZA200807380A patent/ZA200807380B/xx unknown
- 2008-10-07 US US12/246,918 patent/US20090036469A1/en not_active Abandoned
- 2008-10-09 EC EC2008008813A patent/ECSP088813A/es unknown
- 2008-10-10 HN HN2008001530A patent/HN2008001530A/es unknown
- 2008-10-14 NO NO20084291A patent/NO20084291L/no not_active Application Discontinuation
- 2008-11-10 MA MA31375A patent/MA30409B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2649083C (en) | 2011-06-28 |
| MX2008011369A (es) | 2008-09-18 |
| JP2009533473A (ja) | 2009-09-17 |
| HK1131975A1 (en) | 2010-02-12 |
| WO2007121280A1 (en) | 2007-10-25 |
| UA95950C2 (en) | 2011-09-26 |
| AU2007238052A1 (en) | 2007-10-25 |
| RU2431631C2 (ru) | 2011-10-20 |
| BRPI0710710A2 (pt) | 2011-08-16 |
| KR20080108287A (ko) | 2008-12-12 |
| MA30409B1 (fr) | 2009-05-04 |
| AU2007238052B2 (en) | 2011-12-22 |
| NZ571793A (en) | 2011-08-26 |
| AR060403A1 (es) | 2008-06-11 |
| UY30283A1 (es) | 2007-11-30 |
| CN101421252B (zh) | 2011-10-12 |
| TW200815395A (en) | 2008-04-01 |
| HN2008001530A (es) | 2012-01-17 |
| CN101421252A (zh) | 2009-04-29 |
| PE20080186A1 (es) | 2008-04-15 |
| NO20084291L (no) | 2008-11-11 |
| EP2010503A1 (en) | 2009-01-07 |
| CR10249A (es) | 2008-11-26 |
| CA2649083A1 (en) | 2007-10-25 |
| RU2008144578A (ru) | 2010-05-20 |
| US20090036469A1 (en) | 2009-02-05 |
| TNSN08339A1 (en) | 2009-12-29 |
| DOP2007000068A (es) | 2007-10-31 |
| ZA200807380B (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| ECSP099087A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| MX2007003155A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2. | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| ECSP088362A (es) | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 | |
| RU2747431C2 (ru) | Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих | |
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| EA201190303A1 (ru) | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| MX386887B (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas | |
| EA200970852A1 (ru) | Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы | |
| AU2012316912A8 (en) | Novel heterocyclic derivatives and their uses | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| MX2009003100A (es) | Inhibidores de fosfodiesterasa tipo iv. | |
| WO2010084402A3 (en) | Heterocyclic compounds as phosphodiesterase inhibitors | |
| MX2012007711A (es) | Compuestos de piruvamida como inhibidores de alergeno de peptidasa del grupo 1 de acaros del polvo. | |
| AR080527A1 (es) | Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 | |
| MX2013002462A (es) | Compuestos heterociclicos como inhibidores de dgat1. | |
| DOP2009000009A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| UY30505A1 (es) | Fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| TH117954A (th) | สารประกอบเฮเทอโรไซคลิค |